Ziopharm is an oncology-focused company with 3 portfolio products:
1) Darinaparsin, an organic arsenic derivative with in vitro activity against lung, colon, brain, melanoma, ovarian and kidney cancers; hematological cancers (leukemia, lymphoma, myelodysplastic syndromes and multiple myeloma); does not have the cardiac, neurologic or hepatic toxicity of organic arsenic
ASCO 2009: encouraging data in refractory T-cell lymphoma; NHL
Composition of matter patent: expires 2022 (many additional patents)
2) Palifosfamide--Ifosfamide metabolite without the renal and bladder toxicity of Ifosfamide and without the "fuzzy brain" of cyclophasphamide; activity against a wide range of solid tumors
Oct 2009--Phase 2 sarcoma trial stopped early due to better than anticipated efficacy
Composition of matter patent: expires in 2018
3) Indibulin--tubulin antagonist with activity against a wide range of solid tumors
phase 1/2 trial in triple-negative breast cancer due to start Q1 of 2010
Composition of matter patent: expires in 2016; 3 methods of use patents, longest of which is out to 2026 |
